Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy

about

Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis

P2860

Q37288061-0A274240-5DF4-4D46-8639-FD0EE076D421

P2860

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy

Item

http://www.wikidata.org/entity/Q36502057

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Evolution of entecavir-resista ...... dipivoxil combination therapy

@ast

Evolution of entecavir-resista ...... dipivoxil combination therapy

@en

type

Item

label

Evolution of entecavir-resista ...... dipivoxil combination therapy

@ast

Evolution of entecavir-resista ...... dipivoxil combination therapy

@en

prefLabel

Evolution of entecavir-resista ...... dipivoxil combination therapy

@ast

Evolution of entecavir-resista ...... dipivoxil combination therapy

@en

P1476

Evolution of entecavir-resista ...... dipivoxil combination therapy

@en

P2093

Fengmin Lu

http://www.w3.org/2001/XMLSchema#string

L I Zhou

http://www.w3.org/2001/XMLSchema#string

Shaofei Sui

http://www.w3.org/2001/XMLSchema#string

Shuang Liu

http://www.w3.org/2001/XMLSchema#string

Sujun Zheng

http://www.w3.org/2001/XMLSchema#string

Tsen Hua

http://www.w3.org/2001/XMLSchema#string

Y U Chen

http://www.w3.org/2001/XMLSchema#string

Yang Wang

http://www.w3.org/2001/XMLSchema#string

Zhongping Duan

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chronic hepatitis B: update 2009

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Complex dynamics of hepatitis B virus resistance to adefovir.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Grading and staging systems for inflammation and fibrosis in chronic liver diseases.

P304

117-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2015.2855

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26889227

http://www.w3.org/2001/XMLSchema#string

P921

adefovir dipivoxil

P932

4726847

http://www.w3.org/2001/XMLSchema#string

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy

about

P2860

P2860

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932